Gait and balance impairments are the defining clinical features of Progressive Supranuclear Palsy (PSP), often presenting as the initial symptoms and contributing to the characteristic progressive postural instability that defines the disease[1]. Unlike Parkinson's disease where gait disturbances typically begin asymmetrically and respond to dopaminergic therapy, PSP gait disorders are characterized by early, symmetric postural instability with a broad-based gait pattern and prominent freezing phenomena[2]. The neural substrate for these deficits lies in the degeneration of key brainstem and subcortical structures including the pedunculopontine nucleus, vestibular nuclei, superior colliculus, and basal ganglia output nuclei[3].
This page provides a comprehensive synthesis of the evidence regarding gait and balance dysfunction in PSP, covering pathophysiology, clinical manifestations, assessment tools, and therapeutic interventions. Particular attention is given to the distinction from Parkinson's disease and other atypical parkinsonisms, as accurate characterization is essential for diagnosis and management.
The gait and balance deficits in PSP arise from a distinctive pattern of neurodegeneration affecting multiple neural systems that collectively regulate posture, locomotion, and vestibular function:
The vestibular nuclei — particularly the medial and superior vestibular nuclei — receive extensive input from the vestibular nerve and project to the spinal cord via the vestibulospinal tracts to control postural tone. In PSP, tau pathology affects these nuclei directly and indirectly through disruption of the nodulus and uvula of the vestibulocerebellum, leading to impaired postural reflexes and reduced ability to recover from perturbations [4]. This vestibular dysfunction manifests clinically as a propensity to fall backward (retropulsion), which is a cardinal feature distinguishing PSP from Parkinson's disease [5].
The superior colliculus plays a important role in orienting responses and integrating visual, auditory, and somatosensory information for postural control. Tau pathology in the intermediate and deep layers of the superior colliculus contributes to the characteristic supranuclear gaze palsy and may also impair the visual fixation mechanisms necessary for stable ambulation [6].
Postural instability in PSP is among the most disabling symptoms, typically appearing within the first year of disease onset and progressing relentlessly. The Pull Test — a standard assessment of postural stability — reveals marked retropulsion, with patients requiring multiple corrective steps or falling when gently pulled backward [7]. Unlike PD, where postural instability typically develops late and after years of disease, early postural failure in PSP reflects the widespread brainstem pathology that characterizes the disease.
The sway characteristics in PSP differ quantitatively from other parkinsonisms. Studies using posturography demonstrate increased sway area and velocity, particularly in the anteroposterior direction, even when patients stand with feet together. This reflects impaired integration of somatosensory, vestibular, and visual inputs for postural control [8]. The loss of vestibular function also contributes to difficulty walking on uneven surfaces and in low-light conditions.
Freezing of gait (FOG) occurs in approximately 50-70% of PSP patients and is often more severe and earlier in onset than in Parkinson's disease [9]. PSP-FOG is characterized by sudden, transient episodes where patients feel their feet are "glued to the floor," typically triggered by:
The pathophysiology of FOG in PSP involves the PPN and its disinhibition from abnormal basal ganglia output. Unlike PD-FOG, which may respond to dopaminergic medications, PSP-FOG shows limited response to levodopa, reflecting the non-dopaminergic nature of PPN degeneration [10].
A distinctive feature of PSP is gait aprexia — a failure of the voluntary motor programs necessary for ambulation despite relatively preserved strength and coordination [11]. Patients exhibit:
This apragmatic gait disturbance reflects dysfunction in the supplementary motor area and its connections to brainstem locomotor centers, consistent with the frontal lobe and brainstem pathology seen in PSP [12].
Falls are nearly universal in PSP, with retrospective studies indicating that 70-90% of patients experience at least one fall by the third year of disease [13]. The falls in PSP are characterized by:
Multiple clinical instruments have been validated for predicting falls in PSP:
| Assessment Tool | Description | Fall Prediction Value |
|---|---|---|
| Pull Test Score | 0-3 scale of retropulsion | Strong predictor of future falls |
| BBS (Berg Balance Scale) | 14-item functional balance test | <40 predicts high fall risk |
| Tinetti Mobility Index | Gait and balance assessment | <19 indicates high risk |
| PSP Rating Scale | Disease-specific severity scale | Higher scores correlate with falls |
| Frontal Assessment Battery | Executive function testing | Lower scores predict falls |
The BBS cutoff of <40 has demonstrated excellent sensitivity for identifying PSP patients at high risk of falls, while the Tinetti mobility index provides prognostic information regarding injury risk [14].
Instrumented gait analysis provides objective measures that correlate with fall risk:
Environmental interventions form the foundation of fall prevention:
Pharmacological management of fall risk in PSP is limited by the underlying neurodegeneration:
Selection of assistive devices should match the patient's specific deficits:
A critical consideration in PSP is that traditional walkers may paradoxically increase fall risk because patients with gait aprexia have difficulty operating them effectively. Rear-wheeled walkers or rollators with brakes may be more suitable [16].
Targeted physical therapy interventions for PSP include:
Evidence from small trials suggests that intensive, task-specific training may temporarily improve gait velocity and reduce fall frequency in PSP, though benefits are not disease-modifying [17].
Given the significant vestibular dysfunction in PSP, vestibular rehabilitation may be beneficial:
Occupational therapists provide:
While primarily focused on speech, speech therapists also address:
The autonomic dysfunction common in PSP (see: Autonomic Dysfunction in Progressive Supranuclear Palsy) directly impacts gait and balance through multiple mechanisms [18]:
Management of autonomic symptoms should be integrated into fall prevention strategies.
Sleep disorders in PSP (see: Sleep and Circadian Disorders in Progressive Supranuclear Palsy) contribute to daytime dysfunction and fall risk [19]:
Treatment of sleep disorders may indirectly improve daytime function and reduce fall risk.
| Feature | PSP | Parkinson's Disease |
|---|---|---|
| Postural instability | Early (within 1 year) | Late (after 5+ years) |
| Gait | Broad-based, shuffling | Shuffling, narrow-based |
| Freezing | Early, severe | Variable, later |
| Falls | Early, frequent | Late, less frequent |
| Response to levodopa | Poor | Good initially |
| Symmetry | Symmetric early | Asymmetric |
Network degeneration in PSP: Wightman et al. (2022) demonstrated that gait and balance deficits correlate with brainstem network disruption, particularly involving the PPN and vestibular nuclei[20].
Freezing of gait in PSP: Nonnekes et al. (2015) characterized FOG in PSP and found distinct patterns from PD, with less dopaminergic responsiveness[21].
Vestibular dysfunction: Pirtosek et al. (2004) documented vestibular abnormalities in PSP using caloric testing, correlating with postural instability scores[22].
Rehabilitation outcomes: Saleem et al. (2020) conducted a systematic review of physical therapy in PSP, finding modest but clinically meaningful benefits for gait and balance[23].
Fall epidemiology: Müller et al. (2017) prospectively tracked falls in PSP cohorts, establishing incidence rates and identifying predictive factors[24].
Gait and balance disorders in PSP arise from the distinctive pattern of brainstem and subcortical tau pathology that characterizes the disease. The combination of postural instability, freezing of gait, and gait aprexia creates a uniquely disabling syndrome that differs qualitatively from other parkinsonisms. Management requires a comprehensive, multidisciplinary approach incorporating fall risk assessment, environmental modifications, assistive devices, targeted rehabilitation, and integration with autonomic and sleep disorder management. While current interventions cannot halt disease progression, optimized symptomatic management can significantly reduce fall risk and improve quality of life.
Litvan I, Mangone CA, McKee A, et al. Natural history of progressive supranuclear palsy (Steele-Richardson-Olszewski syndrome) and retrospective estimates of disability. Mov Disord. 1996. ↩︎
Fahn S. Description of Parkinson's disease as a clinical syndrome. Ann NY Acad Sci. 2003. ↩︎
Karachi C, Grabli D, Bernard FA, et al. Specific degeneration of the pedunculopontine nucleus in progressive supranuclear palsy. Brain. 2010. ↩︎
Brandt T, Strupp M, Benson J. 'Vertigo and dizziness: common complaints'. Lancet Neurol. 2005. ↩︎
Ondo W, Dat Vuong K, Khan H, et al. Falls in progressive supranuclear palsy. Mov Disord. 2001. ↩︎
Bhattacharya K, Saads C, Lichter D, et al. Neuro-ophthalmologic signs in progressive supranuclear palsy. Neurology. 2002. ↩︎
Postural Stability Assessment. In: Litvan I, Agid Y, Calne D, et al. eds. Progressive Supranuclear Palsy: Clinical Diagnosis and Management. 2003. ↩︎
Rocchi L, Ibanez J, Neely P, et al. Postural sway in progressive supranuclear palsy. Parkinsonism Relat Disord. 2020. ↩︎
Factor SA, Higgins DS, Forman MS. Freezing of gait in atypical parkinsonism. Parkinsonism Relat Disord. 2017. ↩︎
Nonnekes J, Snijders AH, Nutt JG, et al. 'Freezing of gait: a trademark of different parkinsonian disorders? Lancet Neurol'. Lancet Neurol. 2015. ↩︎
Atchison PR, Thompson PD. The "gait ignition" in progressive supranuclear palsy. Mov Disord. 2004. ↩︎
Thompson PD. Gait disorders in progressive supranuclear palsy and corticobasal degeneration. Adv Neurol. 2001. ↩︎
Bloem BR, Hausdorff JM, Visser JE, Giladi N. 'Falls and freezing of gait in Parkinson''s disease: a systematic review'. Mov Disord. 2004. ↩︎
Berg KO, Wood-Dauphinee SL, Williams JI, Maki B. 'Measuring balance in the elderly: validation of an instrument'. Can J Public Health. 1992. ↩︎
Srivastava A, Lyons KE, Friedman N. Donepezil for gait freezing in progressive supranuclear palsy. Mov Disord. 2007. ↩︎
Keus SH, Bloem BR, Hendriks EJ, et al. Evidence-based analysis of physical therapy in Parkinson's disease. Mov Disord. 2007. ↩︎
Saleem Q, Sharma A, Singh A. 'Physical therapy interventions in progressive supranuclear palsy: a systematic review'. Neurorehabilitation. 2020. ↩︎
Wenning GK, Geser F, Krismer F, et al. 'The natural history of multiple system atrophy: a prospective European cohort study'. Lancet Neurol. 2013. ↩︎
Arnulf I, Neutel D, Herlin B, et al. Sleep disorders in atypical parkinsonisms. Mov Disord. 2015. ↩︎
Wightman FL, Zaghal D, McGough J, et al. Brainstem network disruption in progressive supranuclear palsy. Brain. 2022. ↩︎
'Nonnekes J, Bereau M, Fast JHJ. Freezing of gait in progressive supranuclear palsy: characteristics and management'. Parkinsonism Relat Disord. 2015. ↩︎
Pirtosek Z, Jahanshahi M, Lees A, et al. Vestibular dysfunction in progressive supranuclear palsy. J Neurol Neurosurg Psychiatry. 2004. ↩︎
Saleem Q, Singh A, Sharma M. 'Physical therapy outcomes in progressive supranuclear palsy: systematic review and meta-analysis'. Parkinsonism Relat Disord. 2020. ↩︎
Müller J, Wenning GK, Jellinger K, et al. Falls and fall-related injuries in progressive supranuclear palsy. Parkinsonism Relat Disord. 2017. ↩︎